Vivoryon Therapeutics AG (NL:VVY)
:VVY
Want to see NL:VVY full AI Analyst Report?
Total Valuation
Vivoryon Therapeutics AG has a market cap or net worth of €38.65M. The enterprise value is €32.99M.
Market Cap€38.65M
Enterprise Value€32.99M
Share Statistics
Vivoryon Therapeutics AG has 29,614,338 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding29,614,338
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
Vivoryon Therapeutics AG’s return on equity (ROE) is -1.87 and return on invested capital (ROIC) is -136.06%.
Return on Equity (ROE)-1.87
Return on Assets (ROA)-1.18
Return on Invested Capital (ROIC)-136.06%
Return on Capital Employed (ROCE)-1.37
Revenue Per Employee0.00
Profits Per Employee-632.36K
Employee Count14
Asset Turnover0.00
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Vivoryon Therapeutics AG is ―. Vivoryon Therapeutics AG’s PEG ratio is 0.07.
PE Ratio―
PS Ratio0.00
PB Ratio8.11
Price to Fair Value8.11
Price to FCF-4.53
Price to Operating Cash Flow-4.42
PEG Ratio0.07
Income Statement
In the last 12 months, Vivoryon Therapeutics AG had revenue of 0.00 and earned -8.85M in profits. Earnings per share was -0.33.
Revenue0.00
Gross Profit-147.00K
Operating Income-9.18M
Pretax Income-8.85M
Net Income-8.85M
EBITDA-9.03M
Earnings Per Share (EPS)-0.33
Cash Flow
In the last 12 months, operating cash flow was -8.46M and capital expenditures -6.00K, giving a free cash flow of -8.46M billion.
Operating Cash Flow-8.46M
Free Cash Flow-8.46M
Free Cash Flow per Share-0.29
Dividends & Yields
Vivoryon Therapeutics AG pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.80
52-Week Price Change-26.81%
50-Day Moving Average1.37
200-Day Moving Average1.51
Relative Strength Index (RSI)50.02
Average Volume (3m)31.39K
Important Dates
Vivoryon Therapeutics AG upcoming earnings date is Jun 17, 2026, Before Open (Confirmed).
Last Earnings DateApr 23, 2026
Next Earnings DateJun 17, 2026
Ex-Dividend Date―
Financial Position
Vivoryon Therapeutics AG as a current ratio of 7.68, with Debt / Equity ratio of 2.28%
Current Ratio7.68
Quick Ratio7.68
Debt to Market Cap<0.01
Net Debt to EBITDA0.61
Interest Coverage Ratio-203.93
Taxes
In the past 12 months, Vivoryon Therapeutics AG has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00
Enterprise Valuation
Vivoryon Therapeutics AG EV to EBITDA ratio is -3.63, with an EV/FCF ratio of -3.88.
EV to Sales0.00
EV to EBITDA-3.63
EV to Free Cash Flow-3.88
EV to Operating Cash Flow-3.88
Balance Sheet
Vivoryon Therapeutics AG has €5.62M in cash and marketable securities with €108.00K in debt, giving a net cash position of €5.51M billion.
Cash & Marketable Securities€5.62M
Total Debt€108.00K
Net Cash€5.51M
Net Cash Per Share€0.19
Tangible Book Value Per Share€0.15
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
Gross Margin0.00%
Operating Margin0.00%
Pretax Margin0.00%
Net Profit Margin0.00%
EBITDA Margin0.00%
EBIT Margin0.00%
Analyst Forecast
The average price target for Vivoryon Therapeutics AG is ―, which is 11.43% higher than the current price. The consensus rating is ―
Price Target―
Price Target Upside―
Analyst Consensus―
Analyst Count0
Revenue Growth Forecast―
EPS Growth Forecast58.43%